Literature DB >> 24853227

NCCN increases the emphasis on genetic/familial high-risk assessment in colorectal cancer.

Heather Hampel1.   

Abstract

NCCN has developed new guidelines for the assessment of high-risk familial/genetic colorectal cancer, and has positioned these recommendations within the guidelines for detection, prevention, and risk reduction. The Panel recommends that all patients with colorectal cancer be screened for Lynch syndrome, which occurs in 1 of every 35 patients and is the most common form of hereditary colorectal cancer. Such screening could be universal so that all tumors are genetically tested, or screening could be restricted to patients under the age of 70 and those aged 70 and older who meet clinical criteria.
Copyright © 2014 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2014        PMID: 24853227     DOI: 10.6004/jnccn.2014.0200

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  18 in total

1.  A model for patient-direct screening and referral for familial cancer risk.

Authors:  Kristin B Niendorf; Melissa A Geller; Rachel Isaksson Vogel; Timothy R Church; Anna Leininger; Angela Bakke; Robert D Madoff
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

2.  Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.

Authors:  Julia R Trosman; Christine B Weldon; Michael P Douglas; Allison W Kurian; R Kate Kelley; Patricia A Deverka; Kathryn A Phillips
Journal:  J Natl Compr Canc Netw       Date:  2017-02-10       Impact factor: 11.908

3.  Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy.

Authors:  Elizabeth M Jacobi; Gene Landon; Russell R Broaddus; Sinchita Roy-Chowdhuri
Journal:  Arch Pathol Lab Med       Date:  2020-03-30       Impact factor: 5.534

4.  Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.

Authors:  Carlos J Gallego; Brian H Shirts; Caroline S Bennette; Greg Guzauskas; Laura M Amendola; Martha Horike-Pyne; Fuki M Hisama; Colin C Pritchard; William M Grady; Wylie Burke; Gail P Jarvik; David L Veenstra
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

5.  Oncologists' Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer.

Authors:  Aparna R Parikh; Nancy L Keating; Pang-Hsiang Liu; Stacy W Gray; Carrie N Klabunde; Katherine L Kahn; David A Haggstrom; Sapna Syngal; Benjamin Kim
Journal:  J Oncol Pract       Date:  2016-03       Impact factor: 3.840

Review 6.  Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

Authors:  Larissa V Furtado; Wade S Samowitz
Journal:  Virchows Arch       Date:  2017-05-27       Impact factor: 4.064

Review 7.  Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma.

Authors:  Jinru Shia
Journal:  Semin Diagn Pathol       Date:  2015-02-04       Impact factor: 3.464

8.  Clinician-Stakeholders' Perspectives on Using Patient Portals to Return Lynch Syndrome Screening Results.

Authors:  Diane M Korngiebel; Kathleen M West; Wylie Burke
Journal:  J Genet Couns       Date:  2017-11-21       Impact factor: 2.537

9.  Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.

Authors:  Florence Boissière-Michot; Hélène Frugier; Alexandre Ho-Pun-Cheung; Evelyne Lopez-Crapez; Jacqueline Duffour; Frédéric Bibeau
Journal:  Virchows Arch       Date:  2016-05-25       Impact factor: 4.064

10.  Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer.

Authors:  Franceska Dedeurwaerdere; Kathleen Bm Claes; Jo Van Dorpe; Isabelle Rottiers; Joni Van der Meulen; Joke Breyne; Koen Swaerts; Geert Martens
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.